Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cerephex Corporation
Age
22–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patient must have successfully completed study NPT-201 and had an inadequate pain response, defined as \<50% reduction in pain from baseline during participation in NPT-201.
Patient must provide written informed consent and privacy authorization prior to participation in the study.
Female patients of childbearing potential must be willing to use an acceptable method of birth control for the duration of their study participation. Acceptable birth control includes a vasectomized partner, contraceptives (oral, parenteral, or transdermal), intrauterine device, or double barrier method including condoms, sponge, diaphragm, or vaginal ring with spermicidal jellies or cream. Patients considered not of childbearing potential must be surgically sterile (total hysterectomy, bilateral salpingo-oophorectomy, or tubal ligation) or greater than one year post-menopausal, defined as a complete cessation of menstruation for at least one year.
Patients must be willing to refrain from all excluded therapies for the duration of the study.
In the opinion of the Investigator, the patient is willing and able to comply with all protocol-specified requirements.
You may not be if
Patient has a current significant psychological or psychiatric disorder (e.g., severe, unstable or poorly controlled depression, severe anxiety or obsessive-compulsive disorder.
Patient has a score of 2 or 3 on item 9 of the BDI, or, based on the investigator's judgment, the patient is at risk of suicidal ideation or behavior.
Patient has resumed treatment with duloxetine, milnacipran, pregabalin, gabapentin, sodium oxybate or prohibited narcotics.
Female patient who is pregnant, planning a pregnancy, or breastfeeding.
Any anticipated need for surgery that might confound results or interfere with patient's ability to comply with the protocol.
The occurrence of a major protocol violation during the lead-in study indicating a lack of compliance or other significant concern that precludes the patient's ongoing participation.
